Short Interest in LAVA Therapeutics (NASDAQ:LVTX) Drops By 75.5%

LAVA Therapeutics (NASDAQ:LVTX) saw a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 2,400 shares, a drop of 75.5% from the September 30th total of 9,800 shares. Based on an average daily volume of 49,400 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in LAVA Therapeutics stock. XTX Topco Ltd bought a new position in LAVA Therapeutics (NASDAQ:LVTX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 30,807 shares of the company’s stock, valued at approximately $55,000. XTX Topco Ltd owned about 0.12% of LAVA Therapeutics as of its most recent filing with the Securities and Exchange Commission.

LAVA Therapeutics Stock Performance

Shares of LVTX stock remained flat at $2.00 during mid-day trading on Friday. 46,215 shares of the stock were exchanged, compared to its average volume of 598,157. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.39 and a current ratio of 6.39. The firm’s fifty day moving average is $1.71 and its 200-day moving average is $2.13. LAVA Therapeutics has a 52 week low of $1.13 and a 52 week high of $6.47.

LAVA Therapeutics (NASDAQ:LVTX) last released its quarterly earnings data on Tuesday, August 20th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. LAVA Therapeutics had a negative return on equity of 48.53% and a negative net margin of 228.02%. On average, equities research analysts forecast that LAVA Therapeutics will post -1.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

LVTX has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a report on Friday, June 28th. JMP Securities reaffirmed a “market outperform” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a report on Wednesday, August 21st.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.